We’re pleased to announce that Cure EB is joining three other EB charities to fund the clinical development of a new anti-fibrotic drug called TXA127. Click to read press release from Constant Pharmaceuticals.
Scientists at the Sidney Kimmel Cancer Center at Jefferson University have discovered the cause of aggressive skin cancers in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Click to see report from Jefferson University
Krystal Biotech announced that the first patient has been dosed in the Phase 1/2 clinical trial of its drug, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). (source: www.raredr.com, May 10th 2018)
String of major recent grants underlines promise of new potential treatments for Epidermolysis Bullosa and other chronic skin wounds (source: eurekaalert.org, April 12th 2018)
Sohana speaking at #WEDay UK on 9 March 2016
Sharmila Nikapota, the mother of a child with a rare genetic disorder, has high hopes for gene editing…read more